Lars Norgren1, Norbert Weiss2, Sigrid Nikol3, Robert J Hinchliffe4, John C Lantis5, Manesh R Patel6, Holger Reinecke7, Racheli Ofir8, Yael Rosen8, Dan Peres8, Zami Aberman8. 1. Department of Surgery, Faculty of Medicine and Health, Örebro University, Sweden. Electronic address: lars.norgren@regionorebrolan.se. 2. University Centre for Vascular Medicine and Department of Medicine - Section Angiology, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Germany. 3. Asklepios, Klinik St Georg, Hamburg, Germany. 4. Bristol Centre for Surgical Research, Bristol NIHR Biomedical Research Centre, University of Bristol, Bristol, UK. 5. Icahn School of Medicine, New York, NY, USA. 6. Duke University, Durham, NC, USA. 7. Department of Cardiology I - Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital of Muenster, Muenster, Germany. 8. Pluristem Ltd., Haifa, Israel.
Abstract
BACKGROUND:Critical limb ischaemia (CLI) is a life threatening condition with a considerable risk of major amputation and death. Besides revascularisation, no treatment has been proven to reduce the risks. Therapeutic angiogenesis by gene or cell therapy has not demonstrated definitive evidence in randomised controlled trials. PLX-PAD is an "off the shelf" allogeneic placental derived, mesenchymal like cell therapy, which, in preclinical studies, has shown pro-angiogenic, anti-inflammatory, and regenerative properties. Favourable one year amputation free survival (AFS), and trends in reduction of pain scores and increase of tissue perfusion have been shown in two small, open label, phase I trials. METHODS: The PACE study is a phase III randomised, double blind, multicentre, multinational placebo controlled, parallel group study to evaluate the efficacy, tolerability, and safety of intramuscular injections of PLX-PAD cells to treat patients with atherosclerotic CLI with minor tissue loss (Rutherford Category 5) up to the ankle level, who are unsuitable for revascularisation or carry an unfavourable risk benefit for that treatment. The study will enroll 246 patients, who after screening are randomised in a ratio of 2:1 to treatment with intramuscular injections of PLX-PAD 300 × 106 cells or placebo on two occasions, eight weeks apart. The primary efficacy endpoint is time to major amputation or death (amputation free survival), which will be assessed in follow up of at least 12 months and up to 36 months. CONCLUSIONS: Based on favourable pre-clinical and initial clinical study results, the PACE phase III randomised controlled trial will evaluate placenta derived PLX-PAD cell treatment in patients with critical limb ischaemia, with an unfavourable risk benefit for revascularisation. Clinicaltrials.gov: NCT03006770.
RCT Entities:
BACKGROUND:Critical limb ischaemia (CLI) is a life threatening condition with a considerable risk of major amputation and death. Besides revascularisation, no treatment has been proven to reduce the risks. Therapeutic angiogenesis by gene or cell therapy has not demonstrated definitive evidence in randomised controlled trials. PLX-PAD is an "off the shelf" allogeneic placental derived, mesenchymal like cell therapy, which, in preclinical studies, has shown pro-angiogenic, anti-inflammatory, and regenerative properties. Favourable one year amputation free survival (AFS), and trends in reduction of pain scores and increase of tissue perfusion have been shown in two small, open label, phase I trials. METHODS: The PACE study is a phase III randomised, double blind, multicentre, multinational placebo controlled, parallel group study to evaluate the efficacy, tolerability, and safety of intramuscular injections of PLX-PAD cells to treat patients with atherosclerotic CLI with minor tissue loss (Rutherford Category 5) up to the ankle level, who are unsuitable for revascularisation or carry an unfavourable risk benefit for that treatment. The study will enroll 246 patients, who after screening are randomised in a ratio of 2:1 to treatment with intramuscular injections of PLX-PAD 300 × 106 cells or placebo on two occasions, eight weeks apart. The primary efficacy endpoint is time to major amputation or death (amputation free survival), which will be assessed in follow up of at least 12 months and up to 36 months. CONCLUSIONS: Based on favourable pre-clinical and initial clinical study results, the PACE phase III randomised controlled trial will evaluate placenta derived PLX-PAD cell treatment in patients with critical limb ischaemia, with an unfavourable risk benefit for revascularisation. Clinicaltrials.gov: NCT03006770.
Authors: Tobias Winkler; Matthew L Costa; Racheli Ofir; Ornella Parolini; Sven Geissler; Hans-Dieter Volk; Christian Eder Journal: Bone Jt Open Date: 2022-04
Authors: Martin Wolf; Rodolphe W Poupardin; Patricia Ebner-Peking; André Cronemberger Andrade; Constantin Blöchl; Astrid Obermayer; Fausto Gueths Gomes; Balazs Vari; Nicole Maeding; Essi Eminger; Heide-Marie Binder; Anna M Raninger; Sarah Hochmann; Gabriele Brachtl; Andreas Spittler; Thomas Heuser; Racheli Ofir; Christian G Huber; Zami Aberman; Katharina Schallmoser; Hans-Dieter Volk; Dirk Strunk Journal: J Extracell Vesicles Date: 2022-04
Authors: Magdalena Kulus; Rafał Sibiak; Katarzyna Stefańska; Maciej Zdun; Maria Wieczorkiewicz; Hanna Piotrowska-Kempisty; Jędrzej M Jaśkowski; Dorota Bukowska; Kornel Ratajczak; Maciej Zabel; Paul Mozdziak; Bartosz Kempisty Journal: Cells Date: 2021-11-23 Impact factor: 6.600